Le microenvironnement immun et les immunothérapies dans le myélome multiple (notice n° 659512)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03815cam a2200373 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121191923.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gazeau, Nicolas |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Le microenvironnement immun et les immunothérapies dans le myélome multiple |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 47 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Le myélome multiple (MM) se développe au niveau de la moelle osseuse et est toujours précédé de stades précurseurs. En effet, il existe un continuum entre la gammapathie monoclonale de signification indéterminée, le MM asymptomatique, et le MM. Il s’agit là d’un modèle d’évolution défini par des entités cliniques bien individualisées permettant l’étude de l’évolution clonale et du microenvironnement médullaire au cours de la progression de la maladie et ainsi d’en comprendre les étapes phylogéniques. Le microenvironnement médullaire est constitué de cellules stromales, de cellules souches hématopoïétiques, d’ostéoblastes, d’ostéoclastes et de cellules immunitaires dont les lymphocytes T et natural killer, les cellules dendritiques, les monocytes et les cellules myéloïdes suppressives. L’avènement des immunothérapies ces dernières années a réaffirmé de façon remarquable l’importance des mécanismes d’immunoévasion dans l’oncogenèse du MM. La réactivation du système immunitaire suffit à éradiquer des cellules tumorales. Plusieurs types d’immunothérapies ont maintenant une place centrale dans le MM, dont les immunomodulateurs (thalidomide, lénalidomide, pomalidomide et iberdomide), les anti-CD38 (daratumumab et isatuximab), les CAR-T cells et les anticorps bispécifiques. Dans cet article, nous allons exposer les dysfonctionnements du système immunitaire et les mécanismes d’action des principales immunothérapies dans le MM. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Multiple myeloma evolves from a bone marrow clone of plasma cells and is always preceded by a pre-malignant condition. There is a continuum between precursor diseases named gammopathy monoclonal of undetermined significance and smoldering multiple myeloma and multiple myeloma (MM). It represents a model of clonal evolution and evolution of the microenvironment, with well defined clinical stages. The bone marrow microenvironment is constituted of stromal cells, hematopoietic stem cells, osteoblast, osteoclast, and immune cells such as B, T and NK lymphocytes, dendritic cells, macrophages, and myeloid derived suppressor cells. The breakthrough of Immunotherapies has highlighted the importance of immune system in MM oncogenesis. Reactivating the immune system is enough to induce deep response in clinical settings. Several immunotherapies are now essential treatments in MM, such as immunomodulators (thalidomide, lenalidomide, pomalidomide, iberdomide), anti-CD38 (daratumumab and isatuximab), CAR-T cells and bispecific antibodies. In this article we will describe the immune dysfunction and the main immunotherapies in MM. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunoévasion |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lymphocytes T |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anticorps monoclonaux |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lymphocytes NK |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anticorps bispécifiques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunité antitumorale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Myélome multiple |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cellules T à récepteur antigénique chimérique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | monoclonal antibodies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Multiple myeloma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | T cells with chimeric antigen receptor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | NK lymphocytes |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | T lymphocytes |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | bispecific antibodies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | tumor immunity |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunoevasion |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Manier, Salomon |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 26 | N° Supp 2 | 2020-05-15 | p. 4-11 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2020-HS2-page-4?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2020-HS2-page-4?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux